Windtree Therapeutics Statistics
Share Statistics
Windtree Therapeutics has 8.99M shares outstanding. The number of shares has increased by -68.71% in one year.
| Shares Outstanding | 8.99M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 172.12% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.94M |
| Failed to Deliver (FTD) Shares | 69.50K |
| FTD / Avg. Volume | 4.07% |
Short Selling Information
The latest short interest is 195.67K, so 2.24% of the outstanding shares have been sold short.
| Short Interest | 195.67K |
| Short % of Shares Out | 2.24% |
| Short % of Float | 2.25% |
| Short Ratio (days to cover) | 0.06 |
Valuation Ratios
The PE ratio is -0.14 and the forward PE ratio is -0.27.
| PE Ratio | -0.14 |
| Forward PE | -0.27 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0.84 |
| P/FCF Ratio | -0.21 |
| PEG Ratio | n/a |
Enterprise Valuation
Windtree Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 4.49.
| Current Ratio | 1.35 |
| Quick Ratio | 1.35 |
| Debt / Equity | 4.49 |
| Total Debt / Capitalization | 81.79 |
| Cash Flow / Debt | -0.88 |
| Interest Coverage | -350.78 |
Financial Efficiency
Return on equity (ROE) is -5.98% and return on capital (ROIC) is -86.74%.
| Return on Equity (ROE) | -5.98% |
| Return on Assets (ROA) | -0.63% |
| Return on Capital (ROIC) | -86.74% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.01M |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -97.34% in the last 52 weeks. The beta is 0.64, so Windtree Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | -97.34% |
| 50-Day Moving Average | 0.65 |
| 200-Day Moving Average | 4.26 |
| Relative Strength Index (RSI) | 27.35 |
| Average Volume (20 Days) | 1.71M |
Income Statement
In the last 12 months, Windtree Therapeutics had revenue of $0 and earned -$20.29M in profits. Earnings per share was $-92.23.
| Revenue | 0 |
| Gross Profit | -82.00K |
| Operating Income | -17.54M |
| Net Income | -20.29M |
| EBITDA | -20.16M |
| EBIT | - |
| Earnings Per Share (EPS) | -92.23 |
Balance Sheet
The company has $4.32M in cash and $16.83M in debt, giving a net cash position of -$12.51M.
| Cash & Cash Equivalents | 4.32M |
| Total Debt | 16.83M |
| Net Cash | -12.51M |
| Retained Earnings | -844.82M |
| Total Assets | 30.45M |
| Working Capital | -10.50M |
Cash Flow
In the last 12 months, operating cash flow was -$13.44M and capital expenditures -$15.00K, giving a free cash flow of -$13.45M.
| Operating Cash Flow | -13.44M |
| Capital Expenditures | -15.00K |
| Free Cash Flow | -13.45M |
| FCF Per Share | -61.15 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
WINT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -26351.43% |
| FCF Yield | -421.51% |
Analyst Forecast
The average price target for WINT is $7, which is 1900% higher than the current price. The consensus rating is "Hold".
| Price Target | $7 |
| Price Target Difference | 1900% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Apr 22, 2024. It was a backward split with a ratio of 1:18.
| Last Split Date | Apr 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | -40.39 |
| Piotroski F-Score | 0 |